Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population
Authors:
- Kanjaksha GhoshKGKanjaksha Ghosh
- Bipin KulkarniBKBipin Kulkarni
- Vrinda KulkarniVKVrinda Kulkarni
- Cecil RossCRCecil Ross
- Shrimati ShettySSShrimati Shetty
- 1 June 2013
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 710 (1-3) , 80-84
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding ratesBritish Journal of Haematology, 2012
- Genetic factors associated with patient-specific warfarin dose in ethnic IndonesiansBMC Medical Genetics, 2011
- Patient Factors That Influence Warfarin Dose ResponseJournal of Pharmacy Practice, 2010
- Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapyBlood, 2009
- Association of warfarin dose with genes involved in its action and metabolismHuman Genetics, 2006
- Population variation in VKORC1 haplotype structureJournal of Thrombosis and Haemostasis, 2006
- Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patientsJournal of Human Genetics, 2006
- A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivityHuman Molecular Genetics, 2005
- VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulationThrombosis and Haemostasis, 2005
- Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous ThromboembolismNew England Journal of Medicine, 2003